Case Study of Nonalcoholic Steatohepatitis Reversibility in Type 2 Diabetic Patient with Weight Loss Using Liraglutide
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Key messages
- We investigated using GLP1-RA to reverse NASH (F3) in uncontrolled T2M patient.
- Case study of 54y.o kuwaiti male with NASH (F3), that was cured with 15.3% wt loss by using Liraglutide over a 6 months treatment period.
- GLP1-RA are the treatment of choice for our uncontrolled T2D patients targeting the metabolic benefits of wt loss since most of our patients are either over wt or obese with NAFLD.
Presenting Author
Amna Shaghouli MD, FRCPC
Consultant Endocrinologist
Glycemia Clinic
Founder of Glycemia Clinic, Endocrine Clinic - 2013 up to present
Consultant Endocrine and Bone Metabolism Adan teaching Hospital Kuwait - 2013 up to present Active member at Endocrine Society and AACE
Consultant Endocrine Dasman Diabetes Institute, Kuwait, 2009 - 2017
Head of Endocrine Unit Maternity Hospital, Kuwait, 2011- 2012
Consultant Endocrine Ameri Teaching Hospital Kuwait, 2008 - 2011
Fellowship of Endocrinology and Bone Metabolism UofT, Canada 2008.
Canadian Board of Internal Medicine UofT, Canada 2007 GMC (registered in General medical council U.K.) - 1999 MBchB (Leeds medical school 1998)
